1. Schultz Larsen F. (1993) The epidemiology of atopic dermatitis. Monographs in allergy 31: 9—28.
2. Huang C., Sheng Y. Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis. Brandner JM, ed. PLoS ONE. 2014; 9.
3. Spergel J.M., Paller A.S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112 (Suppl 6): S 118—S127.
4. Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol 2008; 9: 68—73.
5. Carr W.W. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatric Drugs 2013; 15 (4): 303—310.
6. Proshutinskaya D.V. Atopicheskiy dermatit u detey. Sovremennyy algoritm lecheniya i kontrolya nad zabolevaniyem. Vestnik dermatologii i venerologii 2016; 2: 65—70. [Прошутинская Д.В. Атопический дерматит у детей. Современный алгоритм лечения и контроля над заболеванием. Вестн дерматол венерол 2016; (2): 65—70.]
7. Kezic S., Novak N., Jakasa I., et al. Skin barrier in atopic dermatitis. Front Biosci 2014; 19: 542—56. Литература
8. Werfel T., Heratizadeh A., Niebuhr M., Kapp A., Roesner L.M., Karch A., et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96—103.
9. Bieber T. Atopic dermatitis. Ann Dermatol. 2010; 22 (2): 125—137.
10. Hanifin J.M., Paller A.S., Eichenfield L., Clark R. A., Korman N., Weinstein G. et al. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 (2, Suppl. 2): S 186—94.
11. Simon D., Lubbe J., Wuthrich B., Wiesner A., Weber M.M., Laffitte E., Anliker M.D., Schoni M.H., Braathen L.R., Schmid-Grendelmeier P., Gilgen Bobalj N., Schneider D.: Benefits from the use of pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice: analysis of a Swiss cohort. Dermatology 2006; 213: 313—318.
12. Mihm M.C., Soter N.A., Dvorak H.F., Austen K.F.: The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976; 67: 305—312.
13. Bangert C., Strober B.E., Cork M., Ortonne J.P., Luger T., Bieber T., Ferguson A., Ecker R.C., Kopp T., Weise-Riccardi S., Guettner A., Stingl G. Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. Dermatology 2011; 222: 36-48.
14. Carr W.W.: Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatr Drugs. 2013 Aug; 15 (4): 303—310.
15. Arellano F.M., Wentworth C.E., Arana A., Fernandez C., Paul C.F. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007; 127: 808—816.
16. Sigurgeirsson B., Boznanski A., Todd G., et al. Safety and eficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015: 135: 597—606.
17. Billich A., Aschauer H., Aszodi A., et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29—35.
18. Kaufmann R., Folster-Holst R., Hoger P., et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004: 114: 1183—8.
19. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003; 4: 641—54.
20. Luger T., De Raeve L., Gelmetti C. et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol 2013; 23: 758—66.